ABT-199 (venetoclax), selectively targeting Bcl-26 but not Bcl-xL to avoid thrombocytopenia7–9, is highly effective against AML cells in vitro and in vivo, and has shown clinical activity in hematologic malignancies10–12. This evidence concerns the gene BCL2L1 and acute myeloid leukemia.